WO2005016970A3 - Fully human antibodies directed against the human insulin-like growth factor-1 receptor - Google Patents
Fully human antibodies directed against the human insulin-like growth factor-1 receptor Download PDFInfo
- Publication number
- WO2005016970A3 WO2005016970A3 PCT/US2004/013852 US2004013852W WO2005016970A3 WO 2005016970 A3 WO2005016970 A3 WO 2005016970A3 US 2004013852 W US2004013852 W US 2004013852W WO 2005016970 A3 WO2005016970 A3 WO 2005016970A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- receptor
- growth factor
- directed against
- antibodies directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2524305A CA2524305C (en) | 2003-05-01 | 2004-05-03 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
EP04775941.0A EP1622942B1 (en) | 2003-05-01 | 2004-05-03 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
JP2006514278A JP2007535895A (en) | 2003-05-01 | 2004-05-03 | Fully human antibody against human insulin-like growth factor-1 receptor |
ES04775941.0T ES2527871T3 (en) | 2003-05-01 | 2004-05-03 | Fully human antibodies directed against human insulin-like growth factor 1 receptor |
US10/555,407 US7638605B2 (en) | 2003-05-01 | 2004-05-03 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
US12/640,671 US7968093B2 (en) | 2003-05-01 | 2009-12-17 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46717703P | 2003-05-01 | 2003-05-01 | |
US60/467,177 | 2003-05-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/555,407 A-371-Of-International US7638605B2 (en) | 2003-05-01 | 2004-05-03 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
US12/640,671 Continuation US7968093B2 (en) | 2003-05-01 | 2009-12-17 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005016970A2 WO2005016970A2 (en) | 2005-02-24 |
WO2005016970A3 true WO2005016970A3 (en) | 2005-04-21 |
Family
ID=34193001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/013852 WO2005016970A2 (en) | 2003-05-01 | 2004-05-03 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
Country Status (6)
Country | Link |
---|---|
US (2) | US7638605B2 (en) |
EP (2) | EP2365001A3 (en) |
JP (2) | JP2007535895A (en) |
CA (1) | CA2524305C (en) |
ES (1) | ES2527871T3 (en) |
WO (1) | WO2005016970A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7667021B2 (en) | 2002-05-24 | 2010-02-23 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US8017735B2 (en) | 2003-11-21 | 2011-09-13 | Schering Corporation | Anti-IGFR1 antibody therapeutic combinations |
US9234041B2 (en) | 2001-01-05 | 2016-01-12 | Pfizer Inc. | Antibodies to insulin-like growth factor I receptor |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
US7559282B2 (en) * | 2002-10-16 | 2009-07-14 | Robert Austin | Monorail sortation system |
US7579157B2 (en) * | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
WO2005072292A2 (en) * | 2004-01-24 | 2005-08-11 | Hugh Mctavish | Methods for enhancing radiation therapy |
US7598350B2 (en) | 2004-03-19 | 2009-10-06 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
JP2008506681A (en) | 2004-07-16 | 2008-03-06 | ファイザー・プロダクツ・インク | Combination therapy for non-blood malignant tumors using anti-IGF-1R antibody |
WO2006060419A2 (en) * | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
PL2100618T3 (en) | 2005-06-17 | 2014-07-31 | Imclone Llc | An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer |
NZ565654A (en) * | 2005-07-18 | 2010-10-29 | Bipar Sciences Inc | Use of iodonitrobenzamide compounds for the treatment of ovarian cancer |
FR2888850B1 (en) * | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
EP1934259A2 (en) * | 2005-10-11 | 2008-06-25 | Ablynx N.V. | Nanobodies and polypeptides against egfr and igf-ir |
EP1979001B1 (en) | 2005-12-13 | 2012-04-11 | Medimmune Limited | Binding proteins specific for insulin-like growth factors and uses thereof |
EP1984011A4 (en) * | 2006-02-03 | 2010-08-18 | Imclone Llc | Igf-ir antagonists as adjuvants for treatment of prostate cancer |
AU2007245164A1 (en) * | 2006-03-28 | 2007-11-08 | Biogen Idec Ma Inc. | Anti-IGF-IR antibodies and uses thereof |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20080112888A1 (en) | 2006-06-30 | 2008-05-15 | Schering Corporation | Igfbp2 biomarker |
WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
JP5537946B2 (en) | 2006-11-22 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Targeted therapeutic agents based on modified proteins for tyrosine kinase receptors including IGF-IR |
TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
US20110262525A1 (en) | 2006-12-13 | 2011-10-27 | Schering Corporation | Methods of treatment |
JP2010518140A (en) * | 2007-02-14 | 2010-05-27 | グラクソ グループ リミテッド | Novel antibody against IGF-1R |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
KR20090113340A (en) * | 2007-03-22 | 2009-10-29 | 임클론 엘엘씨 | Stable antibody formulations |
EP2145021A2 (en) | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
US8178091B2 (en) | 2007-05-21 | 2012-05-15 | University Of Washington | Compositions and methods for the treatment of respiratory disorders |
WO2008152422A2 (en) * | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
PE20090368A1 (en) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | ANTI-IGF ANTIBODIES |
WO2009032145A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
AU2008296386A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of IGF-1R |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
SG185952A1 (en) * | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
WO2009064444A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
AR069393A1 (en) | 2007-11-21 | 2010-01-20 | Imclone Systems Inc | INHIBITION OF THE RECEIVER FOR MACROFAGO STIMULATING PROTEIN (RON) AND METHODS FOR THE TREATMENT OF THE SAME |
US20090149397A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
CA2709029A1 (en) | 2007-12-21 | 2009-07-02 | Bianca Eser | Stability testing of antibodies |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
US20090291088A1 (en) * | 2008-04-11 | 2009-11-26 | Biogen Idec Ma Inc. | Therapeutic combinations of anti-igf-1r antibodies and other compounds |
MX2010011955A (en) | 2008-04-29 | 2011-01-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof. |
US20110129456A1 (en) * | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
US9035027B2 (en) | 2008-06-03 | 2015-05-19 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
NZ589436A (en) | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
NZ590074A (en) | 2008-07-08 | 2012-12-21 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
EA029178B1 (en) | 2008-12-12 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Anti-insulin-like growth factor antibodies, dna molecule, vector, host cell provided for producing this antibody, method for producing same and use |
TW201032796A (en) * | 2009-02-04 | 2010-09-16 | Bipar Sciences Inc | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor |
EP2236139A1 (en) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
CN102481361B (en) | 2009-04-16 | 2014-10-22 | 默沙东公司 | Compositions and methods for treating cancer |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
CA2772628A1 (en) | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US9056907B2 (en) | 2009-10-07 | 2015-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (IGF) system |
AR078651A1 (en) | 2009-10-15 | 2011-11-23 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
CN104928336B (en) | 2009-10-26 | 2020-05-08 | 弗·哈夫曼-拉罗切有限公司 | Method for producing glycosylated immunoglobulins |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US20120220594A1 (en) | 2009-10-30 | 2012-08-30 | Bristol-Meyers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
US20110200595A1 (en) | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
WO2011139973A2 (en) * | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Methods of inhibiting fibrosis using anti-pai-1 antibodies |
EP3091028A1 (en) | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
KR102513760B1 (en) | 2010-06-07 | 2023-03-27 | 암젠 인크 | Drug delivery device |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
AU2011285852B2 (en) | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
KR20130139884A (en) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | Dual variable domain immunoglobulins and uses thereof |
KR101758152B1 (en) * | 2010-10-22 | 2017-07-14 | 삼성전자주식회사 | Apparatus and method for handling network loss in wireless access system |
MX2013008833A (en) | 2011-02-02 | 2013-12-06 | Amgen Inc | Methods and compositons relating to inhibition of igf-1r. |
AU2012236573B2 (en) | 2011-03-31 | 2016-06-02 | Amgen Inc. | Vial adapter and system |
WO2012145507A2 (en) * | 2011-04-19 | 2012-10-26 | Merrimack Pharmaceuticals, Inc. | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
CA3021845C (en) | 2011-04-20 | 2022-03-29 | Amgen Inc. | Autoinjector apparatus |
US20140309229A1 (en) | 2011-10-13 | 2014-10-16 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
ES2675035T3 (en) | 2011-10-14 | 2018-07-05 | Amgen, Inc | Injector and assembly method |
WO2013060872A1 (en) * | 2011-10-27 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
JP6268097B2 (en) | 2011-11-11 | 2018-01-24 | デューク・ユニヴァーシティ | Combination pharmacotherapy for the treatment of solid tumors |
TW201333035A (en) | 2011-12-30 | 2013-08-16 | Abbvie Inc | Dual specific binding proteins directed against IL-13 and/or IL-17 |
EP2631653A1 (en) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
KR20180008921A (en) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
JP2015535464A (en) | 2012-11-21 | 2015-12-14 | アムジエン・インコーポレーテツド | Drug delivery device |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
CA2904448A1 (en) | 2013-03-15 | 2014-09-18 | Tariq Ghayur | Dual specific binding proteins directed against il-1.beta. and/or il-17 |
CA2904661C (en) | 2013-03-15 | 2022-03-15 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
US10092703B2 (en) | 2013-03-15 | 2018-10-09 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
JP6670740B2 (en) | 2013-03-22 | 2020-03-25 | アムジエン・インコーポレーテツド | Injector and assembly method |
AU2014340174B2 (en) | 2013-10-24 | 2019-09-12 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
KR102458637B1 (en) | 2013-10-24 | 2022-10-24 | 암겐 인코포레이티드 | Injector and method of assembly |
US9629801B2 (en) * | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
JP6640113B2 (en) | 2014-05-07 | 2020-02-05 | アムジエン・インコーポレーテツド | Auto-injector with impact reducing element |
JP6822843B2 (en) | 2014-06-03 | 2021-01-27 | アムジエン・インコーポレーテツド | Systems and methods for remotely processing data collected by drug delivery devices |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
JP6716566B2 (en) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | Drug delivery device with proximity sensor |
WO2016100055A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with live button or user interface field |
EP3258988B1 (en) | 2015-02-17 | 2019-08-28 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
ES2905870T3 (en) | 2015-02-27 | 2022-04-12 | Amgen Inc | Drug delivery device having a needle guard mechanism with an adjustable threshold resistance to movement of the needle guard |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
AU2017263558B2 (en) | 2016-05-13 | 2022-12-22 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
MX2019008432A (en) | 2017-01-17 | 2019-11-18 | Amgen Inc | Injection devices and related methods of use and assembly. |
CA3048520A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
JP2020509839A (en) | 2017-03-07 | 2020-04-02 | アムジエン・インコーポレーテツド | Needle insertion due to overpressure |
KR20240005194A (en) | 2017-03-09 | 2024-01-11 | 암겐 인코포레이티드 | Insertion mechanism for drug delivery device |
KR102517342B1 (en) | 2017-03-28 | 2023-03-31 | 암겐 인코포레이티드 | Plunger rod and syringe assembly systems and methods |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019015472A (en) | 2017-06-22 | 2020-02-19 | Amgen Inc | Device activation impact/shock reduction. |
MA49461A (en) | 2017-06-23 | 2020-04-29 | Amgen Inc | ELECTRONIC DRUG DELIVERY DEVICE INCLUDING A CAP ACTIVATED BY A SWITCH ASSEMBLY |
IL270784B2 (en) | 2017-07-14 | 2023-11-01 | Amgen Inc | Needle insertion-retraction system having dual torsion spring system |
IL271173B1 (en) | 2017-07-21 | 2023-12-01 | Amgen Inc | Gas permeable sealing member for drug container and methods of assembly |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US20210332141A1 (en) | 2017-08-30 | 2021-10-28 | Amgen Inc. | Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
MA50528A (en) | 2017-11-03 | 2020-09-09 | Amgen Inc | SYSTEMS AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE |
JP2021501616A (en) | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | Drug delivery device with placement and flow detection |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
EP3706826A1 (en) | 2017-11-10 | 2020-09-16 | Amgen Inc. | Plungers for drug delivery devices |
WO2019099322A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
MX2020004996A (en) | 2017-11-16 | 2020-08-27 | Amgen Inc | Door latch mechanism for drug delivery device. |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MA53320A (en) | 2018-07-31 | 2021-11-03 | Amgen Inc | FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE |
JP2022500095A (en) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | Intervention dosing system and method |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
JP2022503983A (en) | 2018-10-02 | 2022-01-12 | アムジエン・インコーポレーテツド | Injection system for drug delivery with internal force transmission |
CA3112214A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
WO2020081479A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Drug delivery device having damping mechanism |
EA202191038A1 (en) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | METHOD OF PLATFORM ASSEMBLY FOR MEDICINE DELIVERY DEVICE |
US20220031953A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial needle retraction |
US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
EP3873563A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
US11279698B2 (en) | 2018-11-20 | 2022-03-22 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
MX2021012557A (en) | 2019-04-24 | 2021-11-12 | Amgen Inc | Syringe sterilization verification assemblies and methods. |
US20220273887A1 (en) | 2019-08-23 | 2022-09-01 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
CA3217207A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
CN116496403A (en) * | 2022-01-19 | 2023-07-28 | 泽达生物医药有限公司 | anti-PDL 1/IGF1R bispecific antibody, preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2002053596A2 (en) * | 2001-01-05 | 2002-07-11 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
WO2003100008A2 (en) * | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
WO2004071529A2 (en) * | 2003-02-13 | 2004-08-26 | Pfizer Products Inc. | Uses of anti-insulin-like growth factor i receptor antibodies |
WO2004083248A1 (en) * | 2003-03-14 | 2004-09-30 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
WO2004087756A2 (en) * | 2003-04-02 | 2004-10-14 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4774321A (en) | 1986-12-01 | 1988-09-27 | Massachusetts Institute Of Technology | DP100 EGF and insulin-binding protein from Drosophila cells |
ATE90690T1 (en) | 1987-04-06 | 1993-07-15 | Celtrix Pharma | HUMAN SOMATOMEDIN CARRIER PROTEIN SUBUNITS AND METHODS FOR THEIR PRODUCTION. |
US5200509A (en) | 1987-04-06 | 1993-04-06 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides |
ATE243754T1 (en) | 1987-05-21 | 2003-07-15 | Micromet Ag | MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
JPH02503867A (en) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | IL-2 receptor-specific chimeric antibody |
ATE119198T1 (en) | 1988-04-16 | 1995-03-15 | Celltech Ltd | METHOD FOR PRODUCING PROTEINS USING RECOMBINANT DNA. |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH06503711A (en) | 1990-08-28 | 1994-04-28 | カイロン コーポレイション | Novel insulin-like growth factor binding protein (IGFBP-4) |
DK1024191T3 (en) | 1991-12-02 | 2008-12-08 | Medical Res Council | Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries |
US5262308A (en) | 1992-01-28 | 1993-11-16 | Thomas Jefferson University | Cell lines which constitutively express IGF-1 and IGF-1 R |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
US5597563A (en) | 1992-09-04 | 1997-01-28 | Beschorner; William E. | Method induction of antigen-specific immune tolerance |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
EP0694069A1 (en) | 1993-04-06 | 1996-01-31 | Cedars-Sinai Medical Center | Variant insulin-like growth factor i receptor subunits and methods for use thereof |
WO1995019570A1 (en) | 1994-01-14 | 1995-07-20 | Genentech, Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
US5597700A (en) | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
EP0764030B1 (en) | 1994-06-24 | 2000-09-20 | Vladimir P. Torchilin | Composition containing autoantibodies for tumor therapy and prophylaxis |
US5939269A (en) | 1994-12-28 | 1999-08-17 | The Regents Of The University Of California | Antagonists to insulin receptor tyrosine kinase inhibitor |
US6084085A (en) | 1995-11-14 | 2000-07-04 | Thomas Jefferson University | Inducing resistance to tumor growth with soluble IGF-1 receptor |
AUPN999096A0 (en) | 1996-05-22 | 1996-06-13 | Northstar Biologicals Pty Ltd | Peptides, antibodies, vaccines & uses thereof |
US5798266A (en) | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
US6071891A (en) | 1996-11-22 | 2000-06-06 | Regents Of The University Of Minnesota | Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
SK17282000A3 (en) | 1998-05-15 | 2002-04-04 | Imclone Systems Incorporated | Non-radiolabeled protein receptor tyrosine kinase inhibitor |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
JP2002526419A (en) | 1998-10-05 | 2002-08-20 | ファーメクサ エイ/エス | Novel methods for therapeutic vaccination |
EP1006184A1 (en) | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US7329745B2 (en) | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
US20030165502A1 (en) | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
WO2001098493A1 (en) | 2000-06-15 | 2001-12-27 | Kyowa Hakko Kogyo Co., Ltd | Insulin-like growth factor-binding protein |
US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
IL157705A0 (en) | 2001-03-14 | 2004-03-28 | Genentech Inc | Igf antagonist peptides |
US20040116330A1 (en) | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
SI1461359T1 (en) | 2002-01-18 | 2007-06-30 | Pf Medicament | Novel anti-igf-ir antibodies and uses thereof |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
ES2362931T3 (en) | 2002-03-04 | 2011-07-15 | Imclone Llc | SPECIFIC HUMAN ANTIBODIES AGAINST KDR AND USES OF THE SAME. |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
JP5138867B2 (en) | 2002-08-01 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | α-fetoprotein Immu31 antibody and fusion protein and method of use thereof |
US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
EP1651663B1 (en) | 2003-08-08 | 2017-05-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
OA13234A (en) | 2003-08-13 | 2006-12-13 | Pfizer Prod Inc | Modified human IGF-1R antibodies. |
JPWO2005027970A1 (en) | 2003-09-24 | 2007-11-15 | 協和醗酵工業株式会社 | Drugs for cancer treatment |
TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
ES2368741T3 (en) | 2004-02-25 | 2011-11-21 | Dana-Farber Cancer Institute, Inc. | INHIBITORS OF THE RECEPTOR 1 OF THE INSULIN TYPE GROWTH FACTOR TO INHIBIT THE GROWTH OF TUMOR CELLS. |
JP2008506681A (en) | 2004-07-16 | 2008-03-06 | ファイザー・プロダクツ・インク | Combination therapy for non-blood malignant tumors using anti-IGF-1R antibody |
FR2873699B1 (en) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
WO2006060419A2 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
US20060134172A1 (en) | 2004-12-21 | 2006-06-22 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
MX2007012817A (en) | 2005-04-15 | 2007-12-12 | Immunogen Inc | Elimination of heterogeneous or mixed cell population in tumors. |
WO2007000328A1 (en) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
US20070009970A1 (en) | 2005-07-08 | 2007-01-11 | Predicant Biosciences, Inc. | Biological patterns for diagnosis and treatment of cancer |
FR2888850B1 (en) | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
CN101291954B (en) | 2005-08-26 | 2013-03-27 | 罗氏格黎卡特股份公司 | Modified antigen binding molecules with altered cell signaling activity |
EP1979001B1 (en) | 2005-12-13 | 2012-04-11 | Medimmune Limited | Binding proteins specific for insulin-like growth factors and uses thereof |
-
2004
- 2004-05-03 ES ES04775941.0T patent/ES2527871T3/en active Active
- 2004-05-03 JP JP2006514278A patent/JP2007535895A/en not_active Withdrawn
- 2004-05-03 CA CA2524305A patent/CA2524305C/en not_active Expired - Fee Related
- 2004-05-03 US US10/555,407 patent/US7638605B2/en not_active Expired - Fee Related
- 2004-05-03 EP EP10177137A patent/EP2365001A3/en not_active Withdrawn
- 2004-05-03 WO PCT/US2004/013852 patent/WO2005016970A2/en active Application Filing
- 2004-05-03 EP EP04775941.0A patent/EP1622942B1/en not_active Not-in-force
-
2009
- 2009-12-17 US US12/640,671 patent/US7968093B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 JP JP2011058405A patent/JP5638988B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2002053596A2 (en) * | 2001-01-05 | 2002-07-11 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
WO2003100008A2 (en) * | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
WO2004071529A2 (en) * | 2003-02-13 | 2004-08-26 | Pfizer Products Inc. | Uses of anti-insulin-like growth factor i receptor antibodies |
WO2004083248A1 (en) * | 2003-03-14 | 2004-09-30 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
WO2004087756A2 (en) * | 2003-04-02 | 2004-10-14 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
Non-Patent Citations (4)
Title |
---|
BURTRUM DOUGLAS ET AL: "A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.", CANCER RESEARCH, vol. 63, no. 24, 15 December 2003 (2003-12-15), pages 8912 - 8921, XP002316542, ISSN: 0008-5472 * |
HAILEY J ET AL: "NEUTRALIZING ANTI-INSULIN-LIKE GROWTH FACTOR RECEPTOR 1 ANTIBODIES INHIBIT RECEPTOR FUNCTION AND INDUCE RECEPTOR DEGRADATION IN TUMOR CELLS", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 1, no. 14, December 2002 (2002-12-01), pages 1349 - 1353, XP008026465, ISSN: 1535-7163 * |
LU DAN ET AL: "Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 4, 23 January 2004 (2004-01-23), pages 2856 - 2865, XP002316541, ISSN: 0021-9258 * |
VAUGHAN T J ET AL: "HUMAN ANTIBODIES WITH SUB-NANOMOLAR AFFINITIES ISOLATED FROM A LARGE NON-IMMUNIZED PHAGE DISPLAY LIBRARY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 14, 1 March 1996 (1996-03-01), pages 309 - 314, XP000196144, ISSN: 1087-0156 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9234041B2 (en) | 2001-01-05 | 2016-01-12 | Pfizer Inc. | Antibodies to insulin-like growth factor I receptor |
US7667021B2 (en) | 2002-05-24 | 2010-02-23 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US7847068B2 (en) | 2002-05-24 | 2010-12-07 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US7851181B2 (en) | 2002-05-24 | 2010-12-14 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US8017735B2 (en) | 2003-11-21 | 2011-09-13 | Schering Corporation | Anti-IGFR1 antibody therapeutic combinations |
Also Published As
Publication number | Publication date |
---|---|
US20080025990A1 (en) | 2008-01-31 |
WO2005016970A2 (en) | 2005-02-24 |
EP1622942A2 (en) | 2006-02-08 |
JP2011184440A (en) | 2011-09-22 |
US20100158920A1 (en) | 2010-06-24 |
JP2007535895A (en) | 2007-12-13 |
CA2524305C (en) | 2015-12-08 |
EP2365001A3 (en) | 2012-03-28 |
EP1622942B1 (en) | 2014-11-19 |
ES2527871T3 (en) | 2015-02-02 |
CA2524305A1 (en) | 2005-02-24 |
EP2365001A2 (en) | 2011-09-14 |
JP5638988B2 (en) | 2014-12-10 |
US7968093B2 (en) | 2011-06-28 |
US7638605B2 (en) | 2009-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005016970A3 (en) | Fully human antibodies directed against the human insulin-like growth factor-1 receptor | |
WO2003059951A3 (en) | Novel anti-igf-ir antibodies and uses thereof | |
WO2003072036A3 (en) | Treatment methods using anti-cd22 antibodies | |
WO2006138729A3 (en) | Receptor antagonists for treatment of metastatic bone cancer | |
WO2004050016A3 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
WO2003083041A3 (en) | Cripto-specific antibodies | |
WO2005001038A3 (en) | Recombinant anti-cd30 antibodies and uses thereof | |
WO2007012614A3 (en) | Novel anti-igf-ir antibodies and uses thereof | |
MX2009003093A (en) | Compositions and methods relating to glucagon receptor antibodies. | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
WO2005058967A8 (en) | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof | |
WO2000078344A8 (en) | Prion protein peptides and uses thereof | |
WO2002053596A3 (en) | Antibodies to insulin-like growth factor i receptor | |
PL401886A1 (en) | Neutralising, a high-affinity anti-TNF-alpha isolated human antibody, use of this antibody, crystal containing the anti-TNF-alpha human antibody and a preparation containing the crystal | |
WO2005012493A3 (en) | Anti-cd19 antibodies | |
WO2006036877A3 (en) | Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin b-subunit and uses thereof | |
ECSP066526A (en) | ANTIBODIES THAT JOIN THE INTERLEUQUINA-4 RECEIVER | |
WO2001082899A3 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
AU3651802A (en) | Recombinant anti-cd30 antibodies and uses thereof | |
WO2004032857A3 (en) | Antibody therapy | |
WO2003043583A3 (en) | Treatment of immunological disorders using anti-cd30 antibodies | |
WO2003068920A8 (en) | Humanized gm-csf antibodies | |
WO2006099141A3 (en) | Anti-mesothelin antibodies | |
WO2006074390A3 (en) | Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides | |
WO2007035092A3 (en) | Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2524305 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006514278 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004775941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/001458 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 2004775941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10555407 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10555407 Country of ref document: US |